2022 Interim Results
David Marsh, Chief Executive Officer Charmaine Day, Chief Financial 1Officer
Company Overview
Founded by Prof. Michael
McMahon, leading
Laparoscopic surgeon
Leading the change to
sustainable surgical devices
Design & Manufacturing expertise in innovative surgical devices
Direct sales in UK.
Global distribution through
a network of Global
Partners
Focus on Minimally
Invasive Surgery (MIS)
Strong industry partnerships, | |
most recently in robotics, | |
leveraging design expertise | 2 |
Financials
3
Financial Highlights
2022 H1 | Change vs. | 2021 H1 | Change | 2019 H1 | |
prior | |||||
vs pre- | pre- | ||||
comparative | |||||
pandemic | pandemic | ||||
Revenues1 | £5.41m | +28% | £4.22m | +6% | £5.10m |
Underlying | 45.3% | +2.9% | 42.4% | +3.0% | 42.3% |
Gross Margin1 | |||||
Adj. EBITDA2 | £0.29m | +0.44m | £(0.15)m | -0.36m | £0.65m |
Adj. operating | (£0.01)m | +0.14m | £(0.15)m | -0.23m | £0.22m |
(loss)/profit2 | |||||
Adj. (loss)/ | |||||
earnings | (0.004)p | - | (0.004)p | -0.027p | 0.023p |
per share | |||||
(pence)2 |
- Comparative information is shown for the six months ended 30 June 2021 ("2021H1"), except where otherwise stated. Information for the six months ended 30 June 2019 ("2019 H1") has been included to provide a comparison with pre-pandemic trading.
- Adjusted EBITDA, adjusted operating (loss)/ profit and adjusted EPS are stated before deducting non-recurring exceptional costs of £0.03m (2021 H1: nil, 2019 H1: £0.18m), amortisation and impairment of intangible acquisition
costs of £nil (2021 H1: nil, 2019 H1: £0.18m) and share based payment costs of £0.02m (2021 H1 £0.01m, 2019 H1: £0.10m). | 4 |
Revenue Analysis
Revenue by Segment £'m
6.00
5.00
4.00
3.00
2.00
1.00
0.00
H1 2022 | H1 2021 | H1 2020 | H1 2019 |
SI Distribution OEM
SI Brand sales back to relatively normal levels
Distribution showing strong growth, exceeding 2019 and up by 34.7%
OEM recovering with new partner collaborations, additional orders in H2
Continued overall momentum into H2
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Surgical Innovations Group plc published this content on 21 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 September 2022 16:10:02 UTC.